jobstreet com for Indians explained  - Part-Time Flexible Hours
jobstreet com for Indians explained  - Part-Time Flexible Hours
jobstreet com for Indians explained  - Part-Time Flexible Hours
jobstreet com for Indians explained  - Part-Time Flexible Hours
jobstreet com for Indians explained  - Part-Time Flexible Hours
jobstreet com for Indians explained  - Part-Time Flexible Hours
jobstreet com for Indians explained  - Part-Time Flexible Hours
jobstreet com for Indians explained  - Part-Time Flexible Hours

jobstreet com for Indians explained - Part-Time Flexible Hours

₹1798

jobstreet com for Indians explained ✌️【Freelance】✌️Start investing with just ₹500. Leverage AI tools for smart decisions and maximize your profits. Join now!

quantity
Add to Wishlist
Product Description

jobstreet com for Indians explained ✌️【Freelance】✌️Start investing with just ₹500. Leverage AI tools for smart decisions and maximize your profits. Join now!

jobstreet com for Indians explained ✌️【Freelance】✌️Start investing with just ₹500. Leverage AI tools for smart decisions and maximize your profits. Join now!Pharmaceutical giant Dr Reddy’s Laboratories (DRL) saw its shares surge 4.34% on Thursday in an otherwise sluggish market, reaching an intraday high of Rs 1,330.45 following an upgrade by Nomura.The Tokyo-based brokerage has upgraded the stock from ‘Neutral’ to ‘Buy’ with a revised target price of Rs 1,500, down from Rs 6,499, factoring in the 1:5 stock split on October 28.“We assess that risk-reward is favourable and thus upgrade the stock to Buy (from Neutral).

jobstreet com for Indians explained ✌️【Freelance】✌️Begin with ₹500 and earn fast, safe returns month after month.We reduce FY25/26F earnings by 13%/14% to factor in higher overhead costs.

Note that changes to our earnings estimates and target price are due to DRL’s 1:5 stock split,” said Saion Mukherjee and AmlanJyotiDas, research analysts at Nomura.They also said the relative underperformance of the stock suggests that concerns about the high contribution of generic cancer drug gRevlimid are already priced in.

“We think the Street is concerned about the higher contribution from gRevlimid, which could start declining in FY26F.

Further, the overheads have increased significantly in the recent past.

In the first half of FY25, R&D/SG&A were higher by 29%/27% year-on-year.”While the stock has underperformed theNifty PharmaIndex over the past five years, the upgrade reflects Nomura’s confidence in Dr Reddy’s ability to overcome near-term challenges and capitalise on future opportunities.

jobstreet com for Indians explained ✌️【Freelance】✌️Start with ₹500 and earn reliable, high returns each and every month!The stock has risen only 13% over the past year, compared to the Nifty Pharma Index’s 36% growth.

jobstreet com for Indians explained ✌️【Freelance】✌️Invest ₹500 and earn up to 100% returns every month. Start now!The underperformance persists despite a 22.jobstreet com for Indians explained Crypto Investments: Small Capital, Big Rewards

Related Products